Brian Lestini

13.0k total citations
20 papers, 1.0k citations indexed

About

Brian Lestini is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Brian Lestini has authored 20 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brian Lestini's work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (5 papers) and CAR-T cell therapy research (4 papers). Brian Lestini is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (5 papers) and CAR-T cell therapy research (4 papers). Brian Lestini collaborates with scholars based in United States, Germany and Belgium. Brian Lestini's co-authors include Amit Roy, Feng Yan, Shruti Agrawal, Georgia Kollia, Roger Marchant, Kandice Kottke‐Marchant, Sharon M. Sagnella, Bruce Pawel, Gaurav Bajaj and Kelly C. Goldsmith and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Brian Lestini

20 papers receiving 1.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Brian Lestini	566	360	219	194	156	20	1.0k
Hani M. Babiker	670 1.2×	361 1.0×	375 1.7×	166 0.9×	277 1.8×	154	1.5k
Elżbieta Nowara	526 0.9×	359 1.0×	173 0.8×	104 0.5×	220 1.4×	70	1.0k
Lucy Boyce Kennedy	715 1.3×	343 1.0×	235 1.1×	478 2.5×	117 0.8×	20	1.3k
Guohua Yu	447 0.8×	261 0.7×	256 1.2×	137 0.7×	132 0.8×	77	931
Julianne D. Twomey	504 0.9×	302 0.8×	101 0.5×	256 1.3×	93 0.6×	18	988
Alfonso Quintás‐Cardama	797 1.4×	473 1.3×	242 1.1×	334 1.7×	108 0.7×	23	1.3k
Antonio Cubillo	864 1.5×	208 0.6×	253 1.2×	118 0.6×	233 1.5×	88	1.1k
M.F. Spittle	764 1.3×	172 0.5×	211 1.0×	150 0.8×	142 0.9×	44	1.5k
Elaina M. Gartner	964 1.7×	430 1.2×	281 1.3×	302 1.6×	116 0.7×	40	1.7k
W J Urba	722 1.3×	252 0.7×	104 0.5×	510 2.6×	208 1.3×	33	1.3k

Countries citing papers authored by Brian Lestini

Since Specialization

Citations

This map shows the geographic impact of Brian Lestini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Lestini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Lestini more than expected).

Fields of papers citing papers by Brian Lestini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Lestini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Lestini. The network helps show where Brian Lestini may publish in the future.

Co-authorship network of co-authors of Brian Lestini

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Lestini. A scholar is included among the top collaborators of Brian Lestini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Lestini. Brian Lestini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ramalingam, Suresh S., Matthew D. Hellmann, Mark M. Awad, et al.. (2018). Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568. Cancer Research. 78(13_Supplement). CT078–CT078. 57 indexed citations

Yan, Feng, Xiaoning Wang, Gaurav Bajaj, et al.. (2017). Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(18). 5394–5405. 82 indexed citations

Peters, Solange, Federico Cappuzzo, Leora Horn, et al.. (2017). OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057. Journal of Thoracic Oncology. 12(1). S253–S253. 37 indexed citations

Agrawal, Shruti, Feng Yan, Amit Roy, Georgia Kollia, & Brian Lestini. (2016). Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 4(1). 72–72. 158 indexed citations

Wang, Xueyan, Gaurav Bajaj, Manoj Gupta, et al.. (2016). Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. CPT Pharmacometrics & Systems Pharmacology. 6(1). 40–48. 69 indexed citations

Zalcman, Gérard, Naiyer A. Rizvi, H. Léna, et al.. (2015). Phase 2 Study of Nivolumab (ANTI-PROGRAMMED DEATH-1 [PD-1]) in Patients (PTS) with Advanced, Refractory Squamous (SQ) Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 26. i29–i29. 1 indexed citations

Agrawal, Shruti, Feng Yan, Amit Roy, Georgia Kollia, & Brian Lestini. (2015). Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 3(S2). 16 indexed citations

Spigel, David R., Karen L. Reckamp, Naiyer A. Rizvi, et al.. (2015). A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). 8009–8009. 37 indexed citations

Ramalingam, Sundar, Julien Mazières, David Planchard, et al.. (2014). Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 90(5). 1266–1267. 16 indexed citations

10.

Borghaei, Hossein, Thomas J. Lynch, Naiyer A. Rizvi, et al.. (2013). A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 31(15_suppl). TPS8122–TPS8122. 6 indexed citations

11.

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2011). Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Cancer Research. 72(3). 779–789. 170 indexed citations

12.

Su, Fei, Huanming Yang, Brian Higgins, et al.. (2011). Molecular mechanisms underlying disease relapse on treatment with selective BRAF inhibitor vemurafenib (PLX4032).. Journal of Clinical Oncology. 29(15_suppl). 8517–8517. 1 indexed citations

13.

Goldsmith, Kelly C., et al.. (2009). BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death and Differentiation. 17(5). 872–882. 45 indexed citations

14.

Lestini, Brian, Kelly C. Goldsmith, Mark Fluchel, et al.. (2009). Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biology & Therapy. 8(16). 1587–1595. 76 indexed citations

15.

Kreiger, Portia A., Alexander R. Judkins, Pierre A. Russo, et al.. (2008). Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas. Modern Pathology. 22(1). 142–150. 55 indexed citations

16.

Lestini, Brian & Joseph A. Church. (2006). TRICHOSPORON PULLULANS AS A COMPLICATION OF CHRONIC GRANULOMATOUS DISEASE IN A PATIENT UNDERGOING IMMUNOSUPPRESSIVE THERAPY FOR INFLAMMATORY BOWEL DISEASE. The Pediatric Infectious Disease Journal. 25(1). 87–89. 9 indexed citations

17.

Gupta, Anirban Sen, Guofeng Huang, Brian Lestini, et al.. (2004). RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thrombosis and Haemostasis. 93(1). 106–114. 72 indexed citations

18.

Lestini, Brian, Sharon M. Sagnella, Zhong Xu, et al.. (2002). Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. Journal of Controlled Release. 78(1-3). 235–247. 99 indexed citations

19.

Tucker, Robert C., Brian Lestini, & Roger Marchant. (1996). Surface Analysis of Clinically Used Expanded PTFE Endoscopic Tubing Treated By the STERIS PROCESS. ASAIO Journal. 42(4). 306–313. 12 indexed citations

20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact